This is a working overview of angiotensin IV, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-31. Anything still debated is marked as such rather than presented as settled.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Mercapturic acids are condensation products formed from the coupling of cysteine with aromatic compounds. They are formed as conjugates in the liver and are excreted in the urine. Mercapturic acids are formed as part of xenobiotic metabolism. A glutathione S-transferase first conjugates the foreign compound to glutathione, forming an adduct. The adduct is then converted to the mercapturic acid: the γ-glutamate and glycine residues in the glutathione molecule are removed by gamma-glutamyl transpeptidase and dipeptidases. In the final step, the cystine residue in the conjugate is acetylated. The mercapturic acid is then excreted. Levels of mercapturic acids in urine may be used as an indicator of exposure to, e.g., ethylene dibromide, acrylamide, and terbuthylazine.
=== Systems of the body === Pharmacology can focus on specific systems comprising the body. Divisions related to bodily systems study the effects of drugs in different systems of the body. These include neuropharmacology, in the central and peripheral nervous systems; immunopharmacology in the immune system. Other divisions include cardiovascular, renal, and endocrine pharmacology. Psychopharmacology is the study of the use of drugs that affect the psyche, mind, and behavior (e.g. antidepressants) in treating mental disorders (e.g. depression). It incorporates approaches and techniques from neuropharmacology, animal behavior and behavioral neuroscience, and is interested in the behavioral and neurobiological mechanisms of action of psychoactive drugs. The related field of neuropsychopharmacology focuses on the effects of drugs at the overlap between the nervous system and the psyche. Pharmacometabolomics, also known as pharmacometabolomics, is a field which stems from metabolomics, the quantification and analysis of metabolites produced by the body. It refers to the direct measurement of metabolites in an individual's bodily fluids, in order to predict or evaluate the metabolism of pharmaceutical compounds, and to better understand the pharmacokinetic profile of a drug. Pharmacometabolomics can be applied to measure metabolite levels following the administration of a drug, in order to monitor the effects of the drug on metabolic pathways. Pharmacomicrobiomics studies the effect of microbiome variations on drug disposition, action, and toxicity.
== X == XAES – X-ray induced Auger electron spectroscopy XANES – XANES, synonymous with NEXAFS (near edge X-ray absorption fine structure) XAS – X-ray absorption spectroscopy X-CTR – X-ray crystal truncation rod scattering X-ray crystallography XDS – X-ray diffuse scattering XES – X-ray emission spectroscopy XPEEM – X-ray photoelectron emission microscopy XPS – X-ray photoelectron spectroscopy XRD – X-ray diffraction XRES – X-ray resonant exchange scattering XRF – X-ray fluorescence analysis XRR – X-ray reflectivity XRS – X-ray Raman scattering XRT – X-ray transmission XSW – X-ray standing wave technique
The significance of these additional actions for Auvelity's antidepressant effects remains unclear. The combined pharmacological actions of DXM and bupropion make Auvelity function similarly to an SNDRI (serotonin-norepinephrine-dopamine reuptake inhibitor), simultaneously enhancing all three monoamine neurotransmitter systems. This characteristic may contribute to its relatively rapid antidepressant onset. The role of NMDA antagonism in Auvelity appears to be relatively limited. Ketamine and related compounds do indeed owe their rapid antidepressant effects to NMDA receptor antagonism. However, subsequent studies of numerous NMDA antagonists have found that most do not exhibit antidepressant efficacy. The reason appears to be that antidepressant activity requires exceptionally stringent molecular properties for NMDA receptor antagonism, particularly highly specific receptor-binding kinetics. In practice, neither DXM nor dextrorphan fulfills these requirements. This likely explains why Auvelity requires approximately 8 days to produce antidepressant effects, whereas esketamine can begin working within only a few hours. Therefore, although Auvelity substantially shortens the onset of action compared with conventional oral antidepressants, its mechanism underlying the accelerated antidepressant response appears to have only a limited relationship to the rapid antidepressant mechanism of ketamine.
Sources: en.wikipedia.org
== U == Ultradian rhythm A recurrent biological cycle that occurs more than once in 24 hours, such as stages of sleep. In neuroscience, it refers to shorter rhythms regulating hormonal release, arousal, or sleep cycles. Unconditioned response In classical conditioning, an automatic, reflexive response to an unconditioned stimulus (e.g., salivation to food). Studied in behavioral neuroscience. Unconsciousness A state in which an individual is not aware of themselves or their surroundings. Can result from head injury, anesthesia, or metabolic dysfunction. Uncus A structure on the medial surface of the temporal lobe, part of the parahippocampal gyrus. It is involved in olfaction and is adjacent to the amygdala. Undershoot The hyperpolarizing phase following an action potential where membrane potential temporarily becomes more negative than resting potential. Unilateral neglect A neuropsychological condition following damage (typically to the right parietal lobe) in which patients ignore stimuli on one side of space. Unipolar depression A mood disorder characterized by persistent low mood, lack of energy, and anhedonia, without manic episodes. Associated with altered activity in the prefrontal cortex and limbic structures. Unipolar neuron A type of neuron with a single process extending from the cell body. Common in invertebrates and found in human sensory neurons. Upper motor neuron A neuron originating in the cerebral cortex or brainstem that transmits motor signals to lower motor neurons. Damage leads to spasticity, hyperreflexia, and weakness.
=== Fl–Fu === Edith M. Flanigen (born 1929), American chemist known for synthesizing emeralds and zeolites Nicolas Flamel (c. 1330–1418), French alchemist who was believed to have created and discovered the philosopher's stone Paul Flory (1910–1985), American chemist, 1974 Nobel Prize in Chemistry for work on the physical chemistry of macromolecules Maria Forsyth (PhD 1990), Australian chemist known for work on energy storage and on corrosion Margaret D.
The submucosa consists of a dense and irregular layer of connective tissue with blood vessels, lymphatics, and nerves branching into the mucosa and muscular layer. It contains the submucous plexus, and enteric nervous plexus, situated on the inner surface of the muscular layer.
These channels are shut when the membrane potential is near the (negative) resting potential of the cell, but they rapidly begin to open if the membrane potential increases to a precisely defined threshold voltage, "depolarising" the membrane. When the channels open, they allow an inward flow of sodium ions, which makes the interior of the cell more positive, which further raises the (negative) membrane potential. This then causes more channels to open, producing a greater electric current across the cell membrane and so on. The process proceeds explosively until all of the available ion channels are open, resulting in a large upswing in the membrane potential. The rapid influx of sodium ions causes the polarity of (i.e. the direction of the electric field across) the plasma membrane to reverse, and the ion channels then rapidly inactivate. As the sodium channels close, sodium ions can no longer enter the neuron, and they are then actively transported back out of the plasma membrane. Potassium channels are then activated, and there is an outward current of potassium ions, returning the electrochemical gradient to the resting state. Because few ions need to pass through to change the potential, the concentrations of ions on either side remain relatively unchanged during this process. After an action potential has occurred, there is a transient negative shift, called the afterhyperpolarization. In animal cells, there are two primary types of action potentials. One type is generated by voltage-gated sodium channels, the other by voltage-gated calcium channels.
==== Yolk sac ==== The yolk sac is a membranous sac attached to an embryo, formed by cells of the hypoblast layer of the bilaminar embryonic disc. This is alternatively called the umbilical vesicle. In humans, the yolk sac is important in early embryonic blood supply.
Sources: en.wikipedia.org
=== Discretionary spending === Military spending: During 2016, the Department of Defense spent $585 billion, an increase of $1 billion versus 2015. This is a partial measure of all defense-related spending. The military budget of the United States during FY 2014 was approximately $582 billion in expenses for the Department of Defense (DoD), $149 billion for the Department of Veterans Affairs, and $43 billion for the Department of Homeland Security, for a total of $770 billion. This was approximately $33 billion or 4.1% below 2013 spending. DoD spending has fallen from a peak of $678 billion in 2011. The U.S. defense budget (excluding spending for the wars in Iraq and Afghanistan, Homeland Security, and Veteran's Affairs) is around 4% of GDP. Adding these other costs places defense spending around 5% GDP. The DoD baseline budget, excluding supplemental funding for the wars, grew from $297 billion in FY2001 to a budgeted $534 billion for FY2010, an 81% increase. According to the CBO, defense spending grew 9% annually on average from fiscal years 2000–2009. Much of the costs for the wars in Iraq and Afghanistan have not been funded through regular appropriations bills, but through emergency supplemental appropriations bills. As such, most of these expenses were not included in the military budget calculation prior to FY2010. Some budget experts argue that emergency supplemental appropriations bills do not receive the same level of legislative care as regular appropriations bills. During 2011, the U.S. spent more on its military budget than the next 13 countries combined.
The steps of direct ELISA follows the mechanism below: A buffered solution of the antigen to be tested for is added to each well (usually 96-well plates) of a microtiter plate, where it is given time to adhere to the plastic through charge interactions. A solution of non-reacting protein, such as bovine serum albumin or casein, is added to each well in order to cover any plastic surface in the well which remains uncoated by the antigen. The primary antibody with an attached (conjugated) enzyme is added, which binds specifically to the test antigen coating the well. A substrate for this enzyme is then added. Often, this substrate changes color upon reaction with the enzyme. The higher the concentration of the primary antibody present in the serum, the stronger the color change. Often, a spectrometer is used to give quantitative values for color strength. The enzyme acts as an amplifier; even if only a few enzyme-linked antibodies remain bound, the enzyme molecules will produce many signal molecules. Within common-sense limitations, the enzyme can go on producing color indefinitely, but the more antibody is bound, the faster the color will develop. A major disadvantage of the direct ELISA is that the method of antigen immobilization is not specific; when serum is used as the source of test antigen, all proteins in the sample may stick to the microtiter plate well, so small concentrations of analyte in serum must compete with other serum proteins when binding to the well surface.
== Related compounds == The naphthoquinones lawsone methyl ether and methylene-3,3'-bilawsone are some of the active compounds in Impatiens balsamina leaves. Juglone is a structural isomer used as a brown dye. Atovaquone is a synthetic antimicrobial agent that can be manufactured from lawsone.
Produced by Frances Berrigan, directed by Christopher Swayne, made by Cicada Films with the Discovery Channel 8 September The Big G, about gravity; Saturn's gravity destroyed its moons, to make its rings; Newton's laws unleashed the industrial revolution; geophysicist Victoria Lagenheim of the USGS, and gravimetry (gravity mapping); physicist Gabriel Luther; astrophysicist Robert Kirshner of the Harvard-Smithsonian Center for Astrophysics; Andrulla Blanchette; Apollo asteroid (35396) 1997 XF11 will approach the Earth on 26 October 2028 at 600,000 miles; reproductive biologist Lynn Maxey Wiley of UC Davis; neurologist Edward Good; neuroscientist Muriel Ross of NASA Ames; astrobiologist James Clifford of NASA Ames; Ralph Pelligra, chief medical officer at NASA Ames; astronauts Bernard A. Harris Jr. and David Wolf (astronaut); the ISS would be complete by 2004; astrophysicist Alex Filippenko at University of California, Berkeley; astrophysicist Saul Perlmutter at Lawrence Berkeley National Laboratory; astrophysicist Adam Riess of the High-Z Supernova Search Team, who found in 1998 that the universe rate of expansion is increasing, winning the 2011 Nobel Prize for Physics.
== Centers and Institutes for Advanced Research & Education == Center for Advanced Photonics Research Center for Biophysics and Computational Biology Center for Computational Genetics and Genomics Center for Data Analytics and Biomedical Informatics Center for Materials Theory Institute for Computational Molecular Science Sbarro Health Research Organization
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.